(LNSR) LENSAR - Ratings and Ratios

LENSAR, Inc. (NASDAQ:LNSR) is a commercial-stage medical device company specializing in advanced laser technologies for ophthalmic surgery. Founded in 2004 and headquartered in Orlando, Florida, the company is a pioneer in femtosecond laser systems designed to address cataracts and corneal astigmatism. Its flagship product, the LENSAR Laser System, integrates proprietary imaging, procedure planning, and precision technologies to enhance surgical outcomes, efficiency, and reproducibility. The system is particularly noted for its ability to assist surgeons in achieving optimal results by streamlining the procedure and minimizing complications. Additionally, LENSAR offers the ALLY Adaptive Cataract Treatment System, a compact, femtosecond laser-based platform that enables surgeons to perform laser-assisted cataract procedures within a single operating room, combining advanced laser capabilities with ergonomic design.

From a technical perspective, LNSR has shown a bullish trend with its 20-day Simple Moving Average (SMA) at 10.87 and 50-day SMA at 9.69, both below the current price of 13.99. The 200-day SMA at 6.34 further supports the upward momentum. However, the Average True Range (ATR) of 1.00 indicates moderate volatility. On the fundamental side, LENSARs market cap stands at $150.99 million, with a price-to-book (P/B) ratio of 6.64, reflecting a premium valuation relative to book value. The price-to-sales (P/S) ratio of 2.82 suggests a moderate valuation relative to revenue, though the return on equity (RoE) of -73.13% highlights significant profitability challenges.